This patent relates to the method of production of the company's proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. Pending approval from the FDA, the company is currently preparing for its upcoming multi-center Phase II trial in the U.S. with its proprietary NurOwn™ stem cell therapy, which was developed from this method.
"This U.S. patent allowance solidifies our intellectual property protection for our unique production method, as it reinforces the Notice recently received from the European Patent Office for the same technology, announced last week." said Mr. Chaim Lebovits, BrainStorm's President and Principal Executive Officer.
BrainStorm is the exclusive worldwide licensee of this technology from Ramot, the technology transfer company of Tel Aviv University, where it was developed by Professors Daniel Offen and Eldad Melamed.